Skip to main content


Fig. 7 | Cardiovascular Diabetology

Fig. 7

From: The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus

Fig. 7

Risk of lower-limb amputation with SGLT2 inhibitor/canagliflozin. SGLT2, sodium glucose co-transporter 2; T2DM, type 2 diabetes mellitus; CV, cardiovascular. *CANVAS Program results are reported in the on-study population; Canagliflozin Phase 3/4 results are reported in the safety analysis set; Truven results are reported in the intent-to-treat population; EASEL and OBSERVE-4D results are reported in the on-treatment population. Comparison of SGLT2 inhibitor versus non-SGLT2 inhibitor. Data are relative risk (95% CI)

Back to article page